Stocksigma LogoStocksigma Logo

Thyrocare Posts Strong Q2 FY27 Results and Divests Nueclear Healthcare

Thyrocare reported Q2 FY27 consolidated revenue of INR 270.8 Cr (+25.1% YoY) and EBITDA of INR 89.3 Cr (+25.0% YoY) with a 33.0% margin

Thyrocare Posts Strong Q2 FY27 Results and Divests Nueclear Healthcare

Thyrocare Technologies Ltd 路 Investor Presentation 路 29 Oct 2026, 9:47 pm

Thyrocare Posts Strong Q2 FY27 Results and Divests Nueclear Healthcare Thyrocare reported Q2 FY27 consolidated revenue of INR 270.8 Cr (+25.1% YoY) and EBITDA of INR 89.3 Cr (+25.0% YoY) with a 33.0% margin. PAT before exceptions grew 25.7% YoY to INR 60.2 Cr, while reported PAT fell to INR 15.2 Cr due to a one-time INR 45.0 Cr goodwill impairment from divesting Nueclear Healthcare (NHL) for INR 141.4 Cr. Total active franchisees reached 12,911 (+27.1% YoY) and tests performed rose 27.4% YoY to 61.6 Mn. The company remains debt-free.

Original exchange filing (PDF)

More announcements from Thyrocare Technologies Ltd

All Thyrocare Technologies Ltd announcements